Differential efficacy of suicide gene therapy by herpes simplex virus-thymidine kinase gene reflects the status of p53 gene in human esophageal cancer cells

Anticancer Res. 1999 Sep-Oct;19(5B):4157-60.

Abstract

We examined the effect of herpes simplex virus-thymidine kinase gene (HSV-TK)-mediated suicide gene therapy on human esophageal cancer. Two human lines, T.Tn cells which bears truncated p53 and TE2 cells with wild-type p53, were transduced with the HSV-TK gene and tested for their sensitivities to a prodrug, ganciclovir (GCV). The transduced cells, T.Tn/TK and TE2/TK, increased in vitro sensitivity to GCV compared with that of respective wild-type cells. However, the growth suppression of T.Tn/TK tumors induced by GCV was marginal in nude mice and the tumors regrew thereafter. In contrast, the growth of TE2/TK tumors was significantly inhibited by GCV and all the tumors disappeared. The status of the p53 gene of tumor cells thereby may influence the efficacy of the HSV-TK/GCV system.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology
  • Dose-Response Relationship, Drug
  • Esophageal Neoplasms / genetics*
  • Esophageal Neoplasms / therapy*
  • Female
  • Ganciclovir / pharmacology
  • Genes, p53 / genetics*
  • Genetic Therapy / methods*
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Simplexvirus / genetics*
  • Thymidine Kinase / genetics*
  • Time Factors
  • Tumor Cells, Cultured

Substances

  • Antiviral Agents
  • Thymidine Kinase
  • Ganciclovir